CVBT.OB <> Sector: Healthcare <> Industry: Biotechnology

[setravis]

Profile: 



CardioVascular BioTherapeutics, Inc.
1635 Village Center Circle
Suite 250
Las Vegas, NV 89134
United States - Map
Phone: 702-839-7200
Web Site: http://www.cvbt.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 21


BUSINESS SUMMARY   
CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 amino acid form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart, and other tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, which is in Phase I clinical trials for the treatment of diabetic, bedridden, and elderly patients suffering from wounds, open sores, and diabetic ulcers. The company also develops CVBT-141C, which has approval for Phase I clinical trials for the treatment of peripheral artery disease. In addition, CardioVascular BioTherapeutics' product portfolio includes CVBT-141D, which is under proof of concept clinical trials stage for the treatment of disc ischemia. Further, it develops CVBT-141E for the treatment of lumbar ischemia and CVBT-141H for the treatment of severe coronary heart disease?injection catheter delivery, which are under pre-clinical research and development stages. The company was founded in 1998 as CardioVascular Genetic Engineering, Inc. and changed its name to CardioVascular BioTherapeutics, Inc. in 2004. CardioVascular BioTherapeutics is headquartered in Las Vegas, Nevada.

[setravis]

Little company with big ideas ... 
Promising patents...good medical potential.
Big turnaround !
Volume has been the heaviest since this stock started trading 2 years ago.
Shows great promise, though many hurdles to overcome. This is a long-term investment, though !

Long CVBT.OB, speculative play.......Convinced this stock will head higher 
This was a $9 stock, and I am buying here !

Has completed Phase I study of potential blockbuster drug that regenerates capillaries near the heart and effectively bypasses clogged arteries without surgery! Phase II study to begin soon...
Alternative solutions for arthritis, diabetes and high cholesterol ...   



52wk Range: 0.45 - 2.55
Volume: 1,215,976
Avg Vol (3m): 247,317

Technicals
Close Above the 13-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
48.91%above 13-day MA
20.20%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $63.65 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A


Below are the, 6 Month...1 Year...2 Year and 3 Year Charts.......

[setravis]

Press Release Source: CardioVascular BioTherapeutics, Inc.


CardioVascular BioTherapeutics Completes Phase I Wound Healing Trial
Tuesday October 2, 9:00 am ET


LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT - News) today announced the completion of its Phase I wound healing clinical trial aimed at evaluating the safety and tolerability of the company's protein-based drug candidate (CVBT-141B), formulated with human fibroblast growth factor -1 (FGF-1), in patients suffering from either diabetic or venous stasis ulcers. FGF-1 was applied topically in 8 subjects at a single site and was found to be well tolerated.


According to the American College of Foot and Ankle Surgeons, 15 percent of the estimated 20 million Americans afflicted with diabetes will develop a serious foot ulcer during their lifetime. A similar percentage of patients with chronic venous hypertension will also develop wounds. Non-healing dermal ulcers of the lower extremities can lead to infections and amputations. Chronic wounds represent an increasing global health challenge, yet there are currently no universally-accepted standards of care.

FGF-1 offers the possibility of improved dermal ulcer healing by the promotion of new blood vessel growth, known as angiogenesis, in the wound bed resulting in enhanced development of granulation tissue and is able to fill wounds of almost any size. According to the American Diabetes Association, comprehensive foot care programs can reduce amputation rates by 45 to 85 percent.

Dr. Jack Jacobs, CVBT's Chief Operating and Scientific Officer, commented, "We are very pleased to be through our Phase I trial and to see that no serious adverse events were noted in any of the patients receiving FGF-1 topically. With the successful completion of this Phase I study the company can now move on to establish the efficacy of our drug candidate, and in this regard, we are currently finalizing a clinical study protocol for initiating a multiple dose safety and efficacy trial in an expanded patient population." Pre-clinical studies showed that FGF-1 significantly reduced the healing time of full-thickness dermal wounds in normal healthy rats and mice and showed an even greater acceleration of dermal healing in diabetic mice.

The principal investigator for the Phase I study was Thomas Serena, M.D., President of the Newbridge Medical Research Group, a research group specializing in wound healing and vascular surgery, with clinics serving several areas within Western Pennsylvania.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with human FGF-1 as their active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has three clinical trials underway with drug candidates to treat the following medical indications: severe Coronary Heart Disease (CVBT-141H), dermal wound healing in diabetics (CVBT-141B), and Peripheral Arterial Disease (CVBT-141C).

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.



Contact:
CardioVascular BioTherapeutics, Inc.
Investor Relations, 702-839-7220
[email protected]
or
Schwartz Communications
Erin Walsh, 781-684-6532
[email protected]

--------------------------------------------------------------------------------
Source: CardioVascular BioTherapeutics, Inc.